EAN 2026: Meta-analysis finds no added benefit of Radicava/Rilutek combo in ALS

A review from five studies has found no added benefit of using Daiichi Sankyo’s Radicava (edaravone) and Sanofi’s Rilutek ...
UPI

Impax loses Rilutek patent challenge

HAYWARD, Calif., July 27 (UPI) -- U.S. generic drug maker Impax said Friday a federal court has upheld the patent covering Aventis' Rilutek, a generic copy of which Impax hoped to sell. The company ...
MarketWatch

Court rules for Aventis in generic Rilutek patent case

SAN FRANCISCO (CBS.MW) -- A Delaware district court ruled in favor of Aventis Pharmaceuticals in a patent infringement case over IMPAX Laboratories' generic Rilutek drug, IMPAX said on Wednesday. The ...
Times Union

Rilutek helps ALS patients extend life

DEAR DR. DONOHUE: My wife has been diagnosed with amyotrophic lateral sclerosis. She is having some trouble swallowing, and she has slight weakness of her left-side body muscles. She has just started ...
FiercePharma

Bourne Partners and Cerberus Capital Portfolio Company, Covis Pharma, Acquires US Rights from Sanofi for Nilandron®, Plaquenil®, Rilutek®, Uroxatral®, and Kayexalate®

Bourne Partners and Cerberus Capital Portfolio Company, Covis Pharma, Acquires US Rights from Sanofi for Nilandron®, Plaquenil®, Rilutek®, Uroxatral®, and Kayexalate® ZUG Switzerland (April 4, 2013) - ...
FiercePharma

With FDA filing, Mitsubishi Tanabe aims to bring ALS med edavarone to U.S. next year

Japanese drugmaker Mitsubishi Tanabe is hoping to end a drought in the U.S. for new medicines that can treat the devastating neurodegenerative disease amyotrophic lateral sclerosis. The FDA has kicked ...